Quarterly ResultAug 11, 2026, 07:22 AM
Xtant Medical Q2 Revenue Down 34.9%; Reports $9.4M Net Loss
AI Summary
Xtant Medical Holdings, Inc. reported a substantial net loss of $(9.4) million for the second quarter of 2026, a significant reversal from a net income of $3.55 million in the prior year. Total revenue declined by 34.9% to $23.03 million, primarily due to a decrease in product revenue and the absence of license revenue compared to Q2 2025. The company also recognized a $5.0 million write-off related to a distribution agreement deposit, contributing to increased operating expenses and the overall net loss.
Key Highlights
- Reported Q2 2026 net loss of $(9.4) million, a significant decline from $3.55 million net income in Q2 2025.
- Total revenue decreased by 34.9% to $23.03 million in Q2 2026 from $35.41 million in Q2 2025.
- Product revenue fell 24.3% to $23.03 million in Q2 2026 from $30.44 million in Q2 2025.
- Gross profit decreased by 45.1% to $13.33 million in Q2 2026 from $24.28 million in Q2 2025.
- Operating expenses included a $5.0 million write-off of a distribution agreement deposit in Q2 2026.
- Cash and cash equivalents stood at $9.87 million as of June 30, 2026, down from $17.05 million at Dec 31, 2025.
- Total stockholders' equity decreased to $40.02 million from $50.95 million since year-end 2025.
Price Impact
More from XTNT